Evidence map›Paper›PMID 42217113›Full record

ArticleAdvances in therapy2026

Real-World Treatment Patterns, HER2 Testing Practices, and Clinical Outcomes in HER2-Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer.

Yakun Wang, Bo Liu, Jingdong Zhang, Yanqiao Zhang, Xianglin Yuan, Kai Chen, Xianhe Xie, Xiujuan Qu, Liu Yang, Li Zhang and 1 more

Registry-linked trialAbstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06585501 (Treatment and Testing Patterns in HER2-positive Unresectable and Advanced Gastric/ Gastroesophageal Junction Cancer in China), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06585501 completednot on this map

Treatment and Testing Patterns in HER2-positive Unresectable and Advanced Gastric/ Gastroesophageal Junction Cancer in China: A Retrospective Real-world Study (REHEARSAL)

TypeobservationalSponsorDaiichi SankyoRan2024 to 2025Enrolled805ConditionsGastric Cancer, Gastroesophageal Junction CancerArmsNo drug
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yakun Wang *State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing, China.
Bo Liu *Department of Gastroenterology, Shandong Cancer Hospital and Institute, Jinan, China.
Jingdong ZhangDepartment of Gastrointestinal Cancer, Liaoning Cancer Hospital and Institute, Medical Oncology, Shenyang, China.
Yanqiao ZhangDepartment of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Xianglin YuanDepartment of Gastroenterology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Kai ChenDepartment of Oncology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Xianhe XieDepartment of Oncology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Xiujuan QuDepartment of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.
Liu YangDepartment of Medical Oncology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China.
Li ZhangDepartment of Medical Affairs, Daiichi Sankyo (China) Holdings Co., Ltd, Shanghai, China.
Xiaotian ZhangState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing, China. zhangxiaotian@bjmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThis study aimed to assess real-world treatment patterns, human epidermal growth factor receptor 2 (HER2) testing, and clinical outcomes in patients with HER2-positive locally advanced unresectable or metastatic gastric or gastroesophageal junction cancer (GC/GEJC) in China.

methodsA multicenter retrospective study (REHEARSAL Study; NCT06585501) was conducted across nine hospitals in China. Patients with HER2-positive, locally advanced unresectable or metastatic GC/GEJC who initiated first-line therapy were included. Treatment patterns in the first, second, and third lines, HER2 testing practice, and real-world clinical outcomes were assessed.

resultsIn total, 805 patients were included (median age of 62.00 years; 77.14% male and 22.86% female). From 2018 to 2023, the first-line treatment pattern showed an increase in the use of anti-HER2 therapies-from 60.83 to 90.19%. There was a notable increased application of HER2 monoclonal antibody (mAb) with immunotherapy (from 0.83 to 60.78%) in the first line. In the second line, 12.28% of patients were administered vascular endothelial growth factor receptor inhibitor in 2023. HER2-antibody-drug conjugate monotherapy and combination therapy had become the predominant third-line treatment (50.00%) in 2023. Tissue biopsy was the primary sample type for HER2 testing (99.25%). Re-biopsy was performed in 6.96% of cases. Anti-HER2 therapies exhibited benefits with a median real-world progression-free survival of 8.94, 5.52, and 4.96 months in the first-, second-, and third-line settings, respectively.

conclusionIn China, HER2 mAb with or without immunotherapy remained the main first-line option for HER2-positive locally advanced unresectable or metastatic GC/GEJC, with a rising trend toward combination with immunotherapy. The second-line outcomes highlight the urgent need for effective treatment options, underscoring the importance of further real-world studies to better define their role.

trial registrationClinicalTrials.gov identifier, NCT06585501.

Indexed as

Erb-b2 Receptor Tyrosine KinasesEsophageal NeoplasmsEsophagogastric JunctionStomach NeoplasmsAgedChinaFemaleHumansImmunotherapyMaleMiddle AgedRetrospective StudiesTreatment OutcomeERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesAntibody–drug conjugateGastric cancerGastroesophageal junction cancerHuman epidermal growth factor receptor 2-positiveImmunotherapyReal-world evidence

Identifiers

PMID42217113

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.